News | December 14, 2021
Lupin’s Goa plant receives EIR from US FDA
FDA changes inspection classification of the facility to Voluntary Action Indicated
FDA changes inspection classification of the facility to Voluntary Action Indicated
The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity
KOREA PACK and concurrent event ICPI Week (Int’l Cosmetic and Pharmaceutical Industry Week) will be held as hybrid events in 2022
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
The company is focused on the development of novel treatments for RNA viruses
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
The platform’s technology works as a compression algorithm for molecular testing
The Uteshiya facility, licensed by Healthium, will exclusively manufacture Healthium’s arthroscopy portfolio, including patented products in India and U.S.
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
Subscribe To Our Newsletter & Stay Updated
